Barclays Rates Hims & Hers Health (HIMS) buy, $39 Price Target
Barclays analyst Glen Santangelo keeps a buy rating and a $39 price target on Hims & Hers Health, standing out among a mostly cautious Wall Street consensus, a 17.58% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Barclays rated Hims & Hers Health, Inc. ($HIMS) "buy" with a $39 price target on June 18, 2026.
Since the rating, $HIMS is down 7.8% after 1 week, down 7.8% after 1 month and down 20.9% to date (from the $35.47 close on Jun 18, 2026).
HIMS
Hims & Hers Health, Inc.
Key Points
- Barclays reiterated its buy rating on Hims & Hers Health, Inc. NYSE:HIMS with a $39 price target on June 18, 2026.
- Barclays's $39 price target implies 17.58% upside from Hims & Hers Health, Inc.'s ($HIMS) current $33.17 share price.
- The stock trades near $33.17, well above its 200-day moving average of $27.32 as analysts maintain a consensus hold rating.
- Chief Legal Officer Boughton Soleil sold 3,461 shares on October 14, 2026, under a planned trading program.
Get $HIMS trade alerts by text
We text you when insiders, Congress or big funds trade $HIMS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Hims & Hers Health, Inc. alert may contain errors. Disclosures
Barclays Stands Behind Its Buy Rating on Hims & Hers Health
Barclays has reaffirmed its bullish stance on Hims & Hers Health, Inc. NYSE:HIMS, keeping a buy rating and a $39 price target on the telehealth platform on June 18, 2026. Analyst Glen Santangelo pointed to continued growth potential for the digital health company, even as other major financial firms take a more wait-and-see approach on the stock.
Wall Street Analysts Split on Hims & Hers Health Stock
The broader analyst community remains largely neutral on Hims & Hers Health, contrasting with the optimistic view from Barclays. Across 13 analyst opinions, the current consensus recommendation is a hold with a mean price target of $31.15. Truist Securities maintains a hold rating with a $32 price target as of August 24, 2026. Earlier in August, Barclays maintained an overweight rating with a $35 target. Citigroup maintains a neutral rating with a $33 target, Deutsche Bank holds a neutral stance with a $26 target, and Bank of America keeps a neutral rating with a $32 target. TD Cowen maintains a hold rating with a $30 target, Morgan Stanley holds an equal-weight rating with a $28 target, and Needham remains the most bullish alongside Barclays with a buy rating and a $42 price target.
Hims & Hers Health Stock Trades Above Key Moving Averages
Shares of Hims & Hers Health changed hands around $33.17, showing strong momentum over the course of the year. The stock has traded between a 52-week low of $13.74 and a high of $57.45. It currently sits comfortably above its 50-day moving average of $29.40 and its 200-day moving average of $27.32, reflecting solid medium-term gains.
$HIMS price target
Hims & Hers Health, Inc. daily closes and this analyst's $39 target. Not advice.
Insider Buying and Selling at Hims & Hers Health, Inc.
Recent regulatory filings show insider activity on the executive team. Chief Legal Officer Boughton Soleil sold 3,461 shares on October 14, 2026, at an average price of $29.06, for a total value of $100,576.66. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
What Hims & Hers Health Does
Hims & Hers Health operates a direct-to-consumer health and wellness platform linking users with licensed medical professionals in the United States and international markets. The company provides personalized treatments, prescription items, and over-the-counter wellness products spanning mental health, skin care, sexual wellness, and weight management.
What to Watch Next for Hims & Hers Health
Investors will look toward the company's next earnings report scheduled for November 9, 2026, to gauge revenue growth and profitability trends. With a forward P/E ratio of 39.85, market participants will monitor whether consumer demand can support its valuation against a backdrop of cautious analyst ratings.
Related Filing Alerts
Source: Barclays's rating change on $HIMS (Jun 18, 2026). Written by software, not financial advice. How we make alerts